WILLIAM CONTE
- Type
- Physician · Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology
- Where
- Merrillville, IN
- NPI
- 1467794271
- Received
- $1,234,444 in 2,649 records, 2019 to 2025 ($1,224,777 general, $9,666 research)
- As principal investigator
- $510,683 of research payments to others in 18 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 403 | $276,180 |
| 2024 | General payment | 422 | $245,305 |
| 2024 | Research payment | 10 | $1,377 |
| 2023 | General payment | 369 | $176,822 |
| 2023 | Research payment | 1 | $8,289 |
| 2022 | General payment | 491 | $240,215 |
| 2021 | General payment | 361 | $138,946 |
| 2020 | General payment | 275 | $54,207 |
| 2019 | General payment | 317 | $93,100 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 324 | $921,693 |
| Consulting Fee | 55 | $150,191 |
| Travel and Lodging | 413 | $84,988 |
| Food and Beverage | 1,833 | $55,444 |
| Honoraria | 4 | $11,900 |
| Research payment | 11 | $9,666 |
| Education | 9 | $560 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-30 | EMD Serono, Inc. | $690 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Mavenclad Drug, Neurology | 2025 | |
| 2025-12-22 | ARGENX US, INC. | $16 | Food and Beverage | In-kind items and services | VYVGART Drug, Immunology | 2025 | |
| 2025-12-18 | Teva Pharmaceuticals USA, Inc. | $23 | Food and Beverage | In-kind items and services | AUSTEDO XR Drug, Central Nervous System | 2025 | |
| 2025-12-17 | Neurelis, Inc. | $35 | Food and Beverage | In-kind items and services | VALTOCO Drug, EPILEPSY | 2025 | |
| 2025-12-16 | Genentech USA, Inc. | $20 | Food and Beverage | In-kind items and services | Ocrevus Zunovo Biological, Immunology | 2025 | |
| 2025-12-15 | EMD Serono, Inc. | $3,795 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Mavenclad Drug, Neurology | 2025 | |
| 2025-12-15 | EMD Serono, Inc. | $73 | Travel and Lodging | Cash or cash equivalent | Mavenclad Drug, Neurology | 2025 | |
| 2025-12-15 | Mallinckrodt Hospital Products Inc. | $18 | Food and Beverage | In-kind items and services | ACTHAR Biological, IMMUNOLOGY | 2025 | |
| 2025-12-12 | ABBVIE INC. | $34 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2025 | |
| 2025-12-12 | Amgen Inc. | $13 | Food and Beverage | In-kind items and services | UPLIZNA Biological, Inflammation/Rare Disease | 2025 | |
| 2025-12-11 | TG Therapeutics, Inc. | $21 | Food and Beverage | In-kind items and services | BRIUMVI Drug, Immunology | 2025 | |
| 2025-12-10 | Biogen, Inc. | $4,110 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TYSABRI Biological, Neurology | 2025 | |
| 2025-12-10 | Biogen, Inc. | $63 | Travel and Lodging | Cash or cash equivalent | TYSABRI Biological, Neurology | 2025 | |
| 2025-12-10 | Biogen, Inc. | $30 | Food and Beverage | In-kind items and services | TYSABRI Biological, Neurology | 2025 | |
| 2025-12-09 | Biogen, Inc. | $29 | Food and Beverage | In-kind items and services | TYSABRI Biological, Neurology | 2025 | |
| 2025-12-09 | EMD Serono, Inc. | $5 | Food and Beverage | Cash or cash equivalent | 2025 | ||
| 2025-12-04 | EMD Serono, Inc. | $5,175 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Mavenclad Drug, Neurology | 2025 | |
| 2025-12-04 | ARGENX US, INC. | $21 | Food and Beverage | In-kind items and services | VYVGART Drug, Immunology | 2025 | |
| 2025-12-03 | Cycle Pharmaceuticals Inc | $15 | Food and Beverage | Cash or cash equivalent | Bafiertam Drug, Neurology | 2025 | |
| 2025-12-03 | ABBVIE INC. | $14 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2025 | |
| 2025-12-02 | Amgen Inc. | $18 | Food and Beverage | In-kind items and services | UPLIZNA Biological, Inflammation/Rare Disease | 2025 | |
| 2025-12-01 | Vanda Pharmaceuticals Inc. | $34 | Food and Beverage | In-kind items and services | PONVORY Drug, MULTIPLE SCLEROSIS | 2025 | |
| 2025-11-25 | Amneal Pharmaceuticals LLC | $15 | Food and Beverage | In-kind items and services | BREKIYA Drug, NEUROLOGY | 2025 | |
| 2025-11-24 | Aucta Pharmaceuticals, Inc. | $24 | Food and Beverage | In-kind items and services | Motpoly XR Drug, Central Nervous System | 2025 | |
| 2025-11-21 | Teva Pharmaceuticals USA, Inc. | $38 | Food and Beverage | In-kind items and services | AUSTEDO XR Drug, Central Nervous System | 2025 | |
| 2025-11-20 | EMD Serono, Inc. | $287 | Travel and Lodging | Cash or cash equivalent | Mavenclad Drug, Neurology | 2025 | |
| 2025-11-20 | EMD Serono, Inc. | $40 | Food and Beverage | Cash or cash equivalent | 2025 | ||
| 2025-11-20 | EMD Serono, Inc. | $20 | Food and Beverage | Cash or cash equivalent | Mavenclad Drug, Neurology | 2025 | |
| 2025-11-20 | EMD Serono, Inc. | $13 | Food and Beverage | Cash or cash equivalent | Mavenclad Drug, Neurology | 2025 | |
| 2025-11-19 | EMD Serono, Inc. | $64 | Food and Beverage | Cash or cash equivalent | 2025 | ||
| 2025-11-19 | TG Therapeutics, Inc. | $25 | Food and Beverage | In-kind items and services | BRIUMVI Drug, Immunology | 2025 | |
| 2025-11-17 | ABBVIE INC. | $31 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2025 | |
| 2025-11-14 | Amgen Inc. | $14 | Food and Beverage | In-kind items and services | UPLIZNA Biological, Inflammation/Rare Disease | 2025 | |
| 2025-11-13 | EMD Serono, Inc. | $5,175 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Mavenclad Drug, Neurology | 2025 | |
| 2025-11-13 | Genentech USA, Inc. | $22 | Food and Beverage | In-kind items and services | Ocrevus Zunovo Biological, Immunology | 2025 | |
| 2025-11-13 | Novartis Pharmaceuticals Corporation | $16 | Food and Beverage | In-kind items and services | KESIMPTA Drug, Neurology | 2025 | |
| 2025-11-12 | TG Therapeutics, Inc. | $465 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BRIUMVI Drug, Immunology | 2025 | |
| 2025-11-12 | Amgen Inc. | $15 | Food and Beverage | In-kind items and services | UPLIZNA Biological, Inflammation/Rare Disease | 2025 | |
| 2025-11-11 | Alexion Pharmaceuticals, Inc. | $29 | Food and Beverage | In-kind items and services | ULTOMIRIS Biological, Rare Disease | 2025 | |
| 2025-11-11 | EMD Serono, Inc. | $20 | Food and Beverage | Cash or cash equivalent | 2025 | ||
| 2025-11-07 | EMD Serono, Inc. | $54 | Travel and Lodging | Cash or cash equivalent | Mavenclad Drug, Neurology | 2025 | |
| 2025-11-06 | TG Therapeutics, Inc. | $95 | Food and Beverage | In-kind items and services | BRIUMVI Drug, Immunology | 2025 | |
| 2025-11-06 | Biogen, Inc. | $25 | Food and Beverage | In-kind items and services | TYSABRI Biological, Neurology | 2025 | |
| 2025-11-06 | ABBVIE INC. | $11 | Food and Beverage | In-kind items and services | BOTOX Biological, BOTOX THERAPEUTIC | 2025 | |
| 2025-11-05 | Celgene Corporation | $23 | Food and Beverage | Cash or cash equivalent | ZEPOSIA Drug, Neuroscience | 2025 | |
| 2025-11-04 | Novartis Pharmaceuticals Corporation | $20 | Food and Beverage | In-kind items and services | KESIMPTA Drug, Neurology | 2025 | |
| 2025-10-30 | GENZYME CORPORATION | $3,295 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-10-30 | GENZYME CORPORATION | $25 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-10-29 | TG Therapeutics, Inc. | $3,712 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BRIUMVI Drug, Immunology | 2025 | |
| 2025-10-29 | TG Therapeutics, Inc. | $54 | Travel and Lodging | Cash or cash equivalent | BRIUMVI Drug, Immunology | 2025 | |
| 2025-10-29 | TG Therapeutics, Inc. | $20 | Food and Beverage | In-kind items and services | BRIUMVI Drug, Immunology | 2025 | |
| 2025-10-28 | EMD Serono, Inc. | $3,475 | Consulting Fee | Cash or cash equivalent | Mavenclad Drug, Neurology | 2025 | |
| 2025-10-28 | Biogen, Inc. | $29 | Food and Beverage | In-kind items and services | TYSABRI Biological, Neurology | 2025 | |
| 2025-10-27 | ABBVIE INC. | $25 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2025 | |
| 2025-10-24 | EMD Serono, Inc. | $55 | Travel and Lodging | Cash or cash equivalent | Mavenclad Drug, Neurology | 2025 | |
| 2025-10-23 | Teva Pharmaceuticals USA, Inc. | $19 | Food and Beverage | In-kind items and services | AUSTEDO XR Drug, Central Nervous System | 2025 | |
| 2025-10-22 | EMD Serono, Inc. | $48 | Food and Beverage | Cash or cash equivalent | 2025 | ||
| 2025-10-21 | Cycle Pharmaceuticals Inc | $19 | Food and Beverage | Cash or cash equivalent | Bafiertam Drug, Neurology | 2025 | |
| 2025-10-20 | AstraZeneca Pharmaceuticals LP | $26 | Food and Beverage | In-kind items and services | WAINUA Drug, Cardiovascular and Metabolism | 2025 | |
| 2025-10-20 | Genentech USA, Inc. | $23 | Food and Beverage | In-kind items and services | Ocrevus Zunovo Biological, Immunology | 2025 | |
| 2025-10-17 | Amgen Inc. | $22 | Food and Beverage | In-kind items and services | UPLIZNA Biological, Inflammation/Rare Disease | 2025 | |
| 2025-10-16 | PFIZER INC. | $15 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PAIN | 2025 | |
| 2025-10-14 | EMD Serono, Inc. | $5,907 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-10-10 | Axsome Therapeutics, Inc. | $19 | Food and Beverage | In-kind items and services | Sunosi Drug, Neurology | 2025 | |
| 2025-10-09 | TG Therapeutics, Inc. | $3,712 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BRIUMVI Drug, Immunology | 2025 | |
| 2025-10-09 | TG Therapeutics, Inc. | $72 | Travel and Lodging | Cash or cash equivalent | BRIUMVI Drug, Immunology | 2025 | |
| 2025-10-09 | Novartis Pharmaceuticals Corporation | $19 | Food and Beverage | In-kind items and services | KESIMPTA Drug, Neurology | 2025 | |
| 2025-10-09 | Novartis Pharmaceuticals Corporation | $5 | Food and Beverage | In-kind items and services | KESIMPTA Drug, Neurology | 2025 | |
| 2025-10-09 | Novartis Pharmaceuticals Corporation | $3 | Food and Beverage | In-kind items and services | KESIMPTA Drug, Neurology | 2025 | |
| 2025-10-07 | ABBVIE INC. | $21 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2025 | |
| 2025-10-01 | ABBVIE INC. | $14 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2025 | |
| 2025-09-30 | Biogen, Inc. | $26 | Food and Beverage | In-kind items and services | TYSABRI Biological, Neurology | 2025 | |
| 2025-09-30 | Biogen, Inc. | $2 | Food and Beverage | In-kind items and services | TYSABRI Biological, Neurology | 2025 | |
| 2025-09-29 | ABBVIE INC. | $34 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2025 | |
| 2025-09-25 | EMD Serono, Inc. | $5,175 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Mavenclad Drug, Neurology | 2025 | |
| 2025-09-25 | Biogen, Inc. | $26 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-09-24 | Amgen Inc. | $35 | Food and Beverage | In-kind items and services | UPLIZNA Biological, Inflammation/Rare Disease | 2025 | |
| 2025-09-24 | GENZYME CORPORATION | $15 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-09-17 | Amgen Inc. | $18 | Food and Beverage | In-kind items and services | UPLIZNA Biological, Inflammation/Rare Disease | 2025 | |
| 2025-09-17 | Amgen Inc. | $17 | Food and Beverage | In-kind items and services | UPLIZNA Biological, Inflammation/Rare Disease | 2025 | |
| 2025-09-16 | TG Therapeutics, Inc. | $21 | Food and Beverage | In-kind items and services | BRIUMVI Drug, Immunology | 2025 | |
| 2025-09-12 | Amgen Inc. | $19 | Food and Beverage | In-kind items and services | UPLIZNA Biological, Inflammation/Rare Disease | 2025 | |
| 2025-09-11 | Vanda Pharmaceuticals Inc. | $2,875 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | PONVORY Drug, MULTIPLE SCLEROSIS | 2025 | |
| 2025-09-11 | Vanda Pharmaceuticals Inc. | $30 | Food and Beverage | Cash or cash equivalent | PONVORY Drug, MULTIPLE SCLEROSIS | 2025 | |
| 2025-09-11 | Vanda Pharmaceuticals Inc. | $22 | Travel and Lodging | Cash or cash equivalent | PONVORY Drug, MULTIPLE SCLEROSIS | 2025 | |
| 2025-09-10 | TG Therapeutics, Inc. | $232 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BRIUMVI Drug, Immunology | 2025 | |
| 2025-09-10 | EMD Serono, Inc. | $24 | Food and Beverage | Cash or cash equivalent | Mavenclad Drug, Neurology | 2025 | |
| 2025-09-09 | ABBVIE INC. | $10 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2025 | |
| 2025-09-08 | ANI Pharmaceuticals, Inc. | $14 | Food and Beverage | In-kind items and services | PURIFIED CORTROPHIN GEL Drug, Treatment of certain chronic autoimmune disorders including acute exacerbations of MS and RA | 2025 | |
| 2025-09-05 | ABBVIE INC. | $22 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2025 | |
| 2025-09-04 | Biogen, Inc. | $29 | Food and Beverage | In-kind items and services | TYSABRI Biological, Neurology | 2025 | |
| 2025-09-03 | ABBVIE INC. | $16 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2025 | |
| 2025-09-02 | CATALYST PHARMACEUTICALS, INC. | $25 | Food and Beverage | Cash or cash equivalent | FYCOMPA Drug, NEUROLOGY | 2025 | |
| 2025-08-29 | Tonix Medicines, Inc. | $23 | Food and Beverage | In-kind items and services | ZEMBRACE SYMTOUCH Drug, NEUROLOGY | 2025 | |
| 2025-08-29 | Amgen Inc. | $21 | Food and Beverage | In-kind items and services | UPLIZNA Biological, Inflammation/Rare Disease | 2025 | |
| 2025-08-26 | Genentech USA, Inc. | $17 | Food and Beverage | In-kind items and services | Ocrevus Zunovo Biological, Immunology | 2025 | |
| 2025-08-25 | Amgen Inc. | $10 | Food and Beverage | In-kind items and services | UPLIZNA Biological, Inflammation/Rare Disease | 2025 | |
| 2025-08-22 | ABBVIE INC. | $14 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2025 | |
| 2025-08-21 | Novartis Pharmaceuticals Corporation | $15 | Food and Beverage | In-kind items and services | KESIMPTA Drug, Neurology | 2025 | |
| 2025-08-19 | TG Therapeutics, Inc. | $4,387 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BRIUMVI Drug, Immunology | 2025 | |
| 2025-08-19 | TG Therapeutics, Inc. | $319 | Travel and Lodging | In-kind items and services | BRIUMVI Drug, Immunology | 2025 | |
| 2025-08-19 | TG Therapeutics, Inc. | $236 | Travel and Lodging | Cash or cash equivalent | BRIUMVI Drug, Immunology | 2025 | |
| 2025-08-19 | Biogen, Inc. | $25 | Food and Beverage | In-kind items and services | TYSABRI Biological, Neurology | 2025 | |
| 2025-08-19 | TG Therapeutics, Inc. | $15 | Food and Beverage | Cash or cash equivalent | BRIUMVI Drug, Immunology | 2025 | |
| 2025-08-15 | EMD Serono, Inc. | $17 | Food and Beverage | Cash or cash equivalent | 2025 | ||
| 2025-08-13 | Novartis Pharmaceuticals Corporation | $18 | Food and Beverage | In-kind items and services | KESIMPTA Drug, Neurology | 2025 | |
| 2025-08-13 | Novartis Pharmaceuticals Corporation | $7 | Food and Beverage | In-kind items and services | KESIMPTA Drug, Neurology | 2025 | |
| 2025-08-13 | Novartis Pharmaceuticals Corporation | $1 | Food and Beverage | In-kind items and services | KESIMPTA Drug, Neurology | 2025 | |
| 2025-08-12 | TG Therapeutics, Inc. | $145 | Food and Beverage | In-kind items and services | BRIUMVI Drug, Immunology | 2025 | |
| 2025-08-11 | Biogen, Inc. | $343 | Consulting Fee | Cash or cash equivalent | TYSABRI Biological, Neurology | 2025 | |
| 2025-08-08 | EMD Serono, Inc. | $4,463 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Mavenclad Drug, Neurology | 2025 | |
| 2025-08-08 | EMD Serono, Inc. | $264 | Travel and Lodging | Cash or cash equivalent | Mavenclad Drug, Neurology | 2025 | |
| 2025-08-08 | EMD Serono, Inc. | $50 | Travel and Lodging | Cash or cash equivalent | Mavenclad Drug, Neurology | 2025 | |
| 2025-08-08 | Teva Pharmaceuticals USA, Inc. | $30 | Food and Beverage | In-kind items and services | AJOVY Biological, Central Nervous System | 2025 | |
| 2025-08-08 | EMD Serono, Inc. | $15 | Food and Beverage | Cash or cash equivalent | Mavenclad Drug, Neurology | 2025 | |
| 2025-08-07 | Axsome Therapeutics, Inc. | $19 | Food and Beverage | In-kind items and services | Symbravo Drug, Neurology | 2025 | |
| 2025-08-06 | ABBVIE INC. | $19 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2025 | |
| 2025-08-05 | Amgen Inc. | $27 | Food and Beverage | In-kind items and services | UPLIZNA Biological, Inflammation/Rare Disease | 2025 | |
| 2025-08-04 | Biogen, Inc. | $685 | Consulting Fee | Cash or cash equivalent | VUMERITY Drug, Neurology | 2025 | |
| 2025-08-01 | Takeda Pharmaceuticals U.S.A., Inc. | $32 | Food and Beverage | In-kind items and services | HYQVIA Biological, IMMUNOLOGY | 2025 | |
| 2025-07-31 | EMD Serono, Inc. | $4,463 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Mavenclad Drug, Neurology | 2025 | |
| 2025-07-31 | EMD Serono, Inc. | $17 | Food and Beverage | Cash or cash equivalent | 2025 | ||
| 2025-07-31 | PFIZER INC. | $14 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PAIN | 2025 | |
| 2025-07-30 | E.R. Squibb & Sons, L.L.C. | $177 | Travel and Lodging | Cash or cash equivalent | ZEPOSIA Drug, Neuroscience | 2025 | |
| 2025-07-30 | Novartis Pharmaceuticals Corporation | $17 | Food and Beverage | In-kind items and services | KESIMPTA Drug, Neurology | 2025 | |
| 2025-07-30 | E.R. Squibb & Sons, L.L.C. | $10 | Travel and Lodging | Cash or cash equivalent | ZEPOSIA Drug, Neuroscience | 2025 | |
| 2025-07-30 | Novartis Pharmaceuticals Corporation | $7 | Food and Beverage | In-kind items and services | KESIMPTA Drug, Neurology | 2025 | |
| 2025-07-30 | Novartis Pharmaceuticals Corporation | $1 | Food and Beverage | In-kind items and services | KESIMPTA Drug, Neurology | 2025 | |
| 2025-07-28 | EMD Serono, Inc. | $123 | Food and Beverage | Cash or cash equivalent | 2025 | ||
| 2025-07-28 | ABBVIE INC. | $22 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2025 | |
| 2025-07-25 | Amgen Inc. | $23 | Food and Beverage | In-kind items and services | UPLIZNA Biological, Inflammation/Rare Disease | 2025 | |
| 2025-07-25 | Amgen Inc. | $13 | Food and Beverage | In-kind items and services | UPLIZNA Biological, Inflammation/Rare Disease | 2025 | |
| 2025-07-24 | Genentech USA, Inc. | $23 | Food and Beverage | In-kind items and services | Ocrevus Zunovo Biological, Immunology | 2025 | |
| 2025-07-23 | Amgen Inc. | $15 | Food and Beverage | In-kind items and services | UPLIZNA Biological, Inflammation/Rare Disease | 2025 | |
| 2025-07-22 | Vanda Pharmaceuticals Inc. | $2,875 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | PONVORY Drug, MULTIPLE SCLEROSIS | 2025 | |
| 2025-07-22 | Vanda Pharmaceuticals Inc. | $49 | Travel and Lodging | Cash or cash equivalent | PONVORY Drug, MULTIPLE SCLEROSIS | 2025 | |
| 2025-07-22 | Vanda Pharmaceuticals Inc. | $37 | Food and Beverage | Cash or cash equivalent | PONVORY Drug, MULTIPLE SCLEROSIS | 2025 | |
| 2025-07-21 | Amgen Inc. | $15 | Food and Beverage | In-kind items and services | EVENITY Biological, Bone Health | 2025 | |
| 2025-07-18 | GENZYME CORPORATION | $11,074 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-07-18 | GENZYME CORPORATION | $737 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-07-18 | GENZYME CORPORATION | $497 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-07-18 | GENZYME CORPORATION | $154 | Travel and Lodging | Cash or cash equivalent | 2025 | ||
| 2025-07-18 | GENZYME CORPORATION | $112 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-07-18 | GENZYME CORPORATION | $25 | Food and Beverage | Cash or cash equivalent | 2025 | ||
| 2025-07-17 | EMD Serono, Inc. | $25 | Food and Beverage | Cash or cash equivalent | Mavenclad Drug, Neurology | 2025 | |
| 2025-07-17 | Novartis Pharmaceuticals Corporation | $15 | Food and Beverage | In-kind items and services | KESIMPTA Drug, Neurology | 2025 | |
| 2025-07-16 | Amgen Inc. | $19 | Food and Beverage | In-kind items and services | UPLIZNA Biological, Inflammation/Rare Disease | 2025 | |
| 2025-07-14 | EMD Serono, Inc. | $15 | Food and Beverage | Cash or cash equivalent | 2025 | ||
| 2025-07-10 | Biogen, Inc. | $29 | Food and Beverage | In-kind items and services | TYSABRI Biological, Neurology | 2025 | |
| 2025-07-10 | Boston Scientific Corporation | $26 | Food and Beverage | In-kind items and services | General - Embolics Device, General - Embolics_PI | 2025 | |
| 2025-07-09 | EMD Serono, Inc. | $196 | Travel and Lodging | Cash or cash equivalent | Mavenclad Drug, Neurology | 2025 | |
| 2025-07-09 | EMD Serono, Inc. | $121 | Food and Beverage | Cash or cash equivalent | Mavenclad Drug, Neurology | 2025 | |
| 2025-07-09 | EMD Serono, Inc. | $65 | Travel and Lodging | Cash or cash equivalent | Mavenclad Drug, Neurology | 2025 | |
| 2025-07-08 | TG Therapeutics, Inc. | $4,387 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BRIUMVI Drug, Immunology | 2025 | |
| 2025-07-08 | TG Therapeutics, Inc. | $259 | Travel and Lodging | Cash or cash equivalent | BRIUMVI Drug, Immunology | 2025 | |
| 2025-07-08 | TG Therapeutics, Inc. | $191 | Travel and Lodging | In-kind items and services | BRIUMVI Drug, Immunology | 2025 | |
| 2025-07-08 | Celgene Corporation | $20 | Food and Beverage | Cash or cash equivalent | ZEPOSIA Drug, Neuroscience | 2025 | |
| 2025-07-08 | TG Therapeutics, Inc. | $17 | Food and Beverage | Cash or cash equivalent | BRIUMVI Drug, Immunology | 2025 | |
| 2025-07-07 | E.R. Squibb & Sons, L.L.C. | $54 | Travel and Lodging | Cash or cash equivalent | ZEPOSIA Drug, Neuroscience | 2025 | |
| 2025-07-02 | Vanda Pharmaceuticals Inc. | $34 | Food and Beverage | In-kind items and services | PONVORY Drug, MULTIPLE SCLEROSIS | 2025 | |
| 2025-07-01 | E.R. Squibb & Sons, L.L.C. | $2,320 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ZEPOSIA Drug, Neuroscience | 2025 | |
| 2025-07-01 | SK Life Science, Inc. | $27 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-06-26 | Alexion Pharmaceuticals, Inc. | $2,950 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ULTOMIRIS Biological, Rare Disease | 2025 | |
| 2025-06-26 | Novartis Pharmaceuticals Corporation | $18 | Food and Beverage | In-kind items and services | KESIMPTA Drug, Neurology | 2025 | |
| 2025-06-26 | EMD Serono, Inc. | $14 | Food and Beverage | Cash or cash equivalent | 2025 | ||
| 2025-06-25 | Vanda Pharmaceuticals Inc. | $29 | Food and Beverage | In-kind items and services | PONVORY Drug, MULTIPLE SCLEROSIS | 2025 | |
| 2025-06-24 | ABBVIE INC. | $15 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-06-23 | TG Therapeutics, Inc. | $27 | Food and Beverage | In-kind items and services | BRIUMVI Drug, Immunology | 2025 | |
| 2025-06-18 | ABBVIE INC. | $17 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2025 | |
| 2025-06-17 | EMD Serono, Inc. | $4,463 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Mavenclad Drug, Neurology | 2025 | |
| 2025-06-17 | PFIZER INC. | $16 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PAIN | 2025 | |
| 2025-06-17 | Vanda Pharmaceuticals Inc. | $4 | Food and Beverage | In-kind items and services | PONVORY Drug, MULTIPLE SCLEROSIS | 2025 | |
| 2025-06-16 | Novartis Pharmaceuticals Corporation | $18 | Food and Beverage | In-kind items and services | KESIMPTA Drug, Neurology | 2025 | |
| 2025-06-16 | Novartis Pharmaceuticals Corporation | $6 | Food and Beverage | In-kind items and services | KESIMPTA Drug, Neurology | 2025 | |
| 2025-06-16 | Novartis Pharmaceuticals Corporation | $2 | Food and Beverage | In-kind items and services | KESIMPTA Drug, Neurology | 2025 | |
| 2025-06-13 | Amgen Inc. | $15 | Food and Beverage | In-kind items and services | UPLIZNA Biological, Inflammation/Rare Disease | 2025 | |
| 2025-06-12 | EMD Serono, Inc. | $46 | Food and Beverage | Cash or cash equivalent | 2025 | ||
| 2025-06-11 | Alexion Pharmaceuticals, Inc. | $62 | Travel and Lodging | Cash or cash equivalent | ULTOMIRIS Biological, Rare Disease | 2025 | |
| 2025-06-11 | Amgen Inc. | $13 | Food and Beverage | In-kind items and services | UPLIZNA Biological, Inflammation/Rare Disease | 2025 | |
| 2025-06-11 | Novartis Pharmaceuticals Corporation | $4 | Food and Beverage | In-kind items and services | KESIMPTA Drug, Neurology | 2025 | |
| 2025-06-10 | EMD Serono, Inc. | $5,653 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Mavenclad Drug, Neurology | 2025 | |
| 2025-06-10 | EMD Serono, Inc. | $4,463 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Mavenclad Drug, Neurology | 2025 | |
| 2025-06-10 | EMD Serono, Inc. | $3,273 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Mavenclad Drug, Neurology | 2025 | |
| 2025-06-10 | EMD Serono, Inc. | $2,083 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-06-10 | Biogen, Inc. | $29 | Food and Beverage | In-kind items and services | TYSABRI Biological, Neurology | 2025 | |
| 2025-06-06 | EMD Serono, Inc. | $446 | Travel and Lodging | Cash or cash equivalent | Mavenclad Drug, Neurology | 2025 | |
| 2025-06-06 | EMD Serono, Inc. | $62 | Travel and Lodging | Cash or cash equivalent | Mavenclad Drug, Neurology | 2025 | |
| 2025-06-06 | EMD Serono, Inc. | $22 | Food and Beverage | Cash or cash equivalent | Mavenclad Drug, Neurology | 2025 | |
| 2025-06-05 | Celgene Corporation | $20 | Food and Beverage | Cash or cash equivalent | ZEPOSIA Drug, Neuroscience | 2025 | |
| 2025-06-04 | Amgen Inc. | $22 | Food and Beverage | In-kind items and services | UPLIZNA Biological, Inflammation/Rare Disease | 2025 | |
| 2025-05-30 | GENZYME CORPORATION | $89 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-05-30 | Amgen Inc. | $21 | Food and Beverage | In-kind items and services | UPLIZNA Biological, Inflammation/Rare Disease | 2025 | |
| 2025-05-30 | Novartis Pharmaceuticals Corporation | $14 | Food and Beverage | In-kind items and services | KESIMPTA Drug, Neurology | 2025 | |
| 2025-05-29 | TG Therapeutics, Inc. | $3,712 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v (3 payments) | Cash or cash equivalent | BRIUMVI Drug, Immunology | 2025 | |
| 2025-05-29 | TG Therapeutics, Inc. | $675 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v (3 payments) | Cash or cash equivalent | BRIUMVI Drug, Immunology | 2025 | |
| 2025-05-29 | TG Therapeutics, Inc. | $559 | Travel and Lodging (3 payments) | In-kind items and services | BRIUMVI Drug, Immunology | 2025 | |
| 2025-05-29 | TG Therapeutics, Inc. | $279 | Travel and Lodging (3 payments) | Cash or cash equivalent | BRIUMVI Drug, Immunology | 2025 | |
| 2025-05-29 | TG Therapeutics, Inc. | $197 | Travel and Lodging (3 payments) | Cash or cash equivalent | BRIUMVI Drug, Immunology | 2025 | |
| 2025-05-29 | Alexion Pharmaceuticals, Inc. | $31 | Food and Beverage | In-kind items and services | ULTOMIRIS Biological, Rare Disease | 2025 | |
| 2025-05-29 | TG Therapeutics, Inc. | $19 | Food and Beverage | In-kind items and services | BRIUMVI Drug, Immunology | 2025 |
The latest 200 records of 2,649.
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2025-11-17 | GENZYME CORPORATION | Methodist Hospitals Inc | $14,495 | Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalima | 2025 |
| 2025-10-28 | Novartis Pharmaceuticals Corporation | METHODIST HOSPITALS NEUROSCIENCE INSTITUTE | $102 | A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus | 2025 |
| 2025-07-28 | GENZYME CORPORATION | Methodist Hospitals Inc | $18,804 | A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Pa | 2025 |
| 2025-02-20 | Novartis Pharmaceuticals Corporation | Methodist Hospitals Inc | $15,298 | A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus | 2025 |
| 2025-01-13 | GENZYME CORPORATION | Methodist Hospitals Inc | $2,336 | A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Pa | 2025 |
| 2025-01-13 | GENZYME CORPORATION | Methodist Hospitals Inc | $8,525 | A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Pa | 2025 |
| 2025-01-09 | Novartis Pharmaceuticals Corporation | METHODIST HOSPITALS NEUROSCIENCE INSTITUTE | $12,998 | A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus | 2025 |
| 2024-09-04 | GENZYME CORPORATION | METHODIST HOSPITALS INC | $12,675 | A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Pa | 2024 |
| 2024-08-05 | GENZYME CORPORATION | METHODIST HOSPITALS INC | $11,880 | A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Pa | 2024 |
| 2024-07-02 | GENZYME CORPORATION | METHODIST HOSPITALS INC | $11,880 | Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalima | 2024 |
| 2024-02-15 | Novartis Pharmaceuticals Corporation | METHODIST HOSPITALS INC | $15,542 | A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus | 2024 |
| 2024-01-09 | Novartis Pharmaceuticals Corporation | METHODIST HOSPITALS NEUROSCIENCE INSTITUTE | $78,738 | A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus | 2024 |
| 2023-04-07 | Novartis Pharmaceuticals Corporation | Methodist Hospitals Inc | $58,432 | A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus | 2023 |
| 2023-01-09 | Novartis Pharmaceuticals Corporation | METHODIST HOSPITALS NEUROSCIENCE INSTITUTE | $182,718 | A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus | 2023 |
| 2022-08-15 | GENZYME CORPORATION | METHODIST HOSPITALS INC | $9,200 | A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Nonre | 2022 |
| 2022-04-11 | GENZYME CORPORATION | METHODIST HOSPITALS INC | $9,200 | A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Prima | 2022 |
| 2022-03-31 | Novartis Pharmaceuticals Corporation | METHODIST HOSPITALS INC | $46,639 | A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL-GROUP STUDY, COMPARING THE EFFICACY AND SAFETY OF REMIBRUTINIB VERSUS | 2022 |
| 2021-01-20 | Novartis Pharmaceuticals Corporation | Methodist Hospitals Inc | $1,214 | LONG TERM PROSPECTIVE MULTINATIONAL PARALLEL COHORT STUDY MONITORING SAFETY IN PATIENTS WITH MULTIPLE SCLEROSIS NEWLY ST | 2021 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Merrillville, IN, county Lake County, IN, state Indiana; placed by its city name.
| Measure | Place (city or town) Merrillville, IN | County Lake County, IN | State Indiana |
|---|---|---|---|
| Population B01003 | 36,476 | 500,379 | 6,851,073 |
| Population, 2020 census P1 | 36,444 | 498,700 | 6,785,528 |
| Median age B01002 | 42.4 | 39.7 | 38.1 |
| Under 18 B01001 | 20.5% | 23.2% | 23.3% |
| 65 and over B01001 | 20.7% | 17.9% | 16.8% |
| Households B11001 | 15,487 | 195,130 | 2,716,009 |
| Foreign born B05002 | 6.3% | 7.3% | 6.3% |
| Median household income B19013 | $67,587 | $71,493 | $71,957 |
| Median family income B19113 | $84,257 | $88,760 | $90,767 |
| Per capita income B19301 | $36,629 | $37,284 | $38,351 |
| Poverty rate B17001 | 12.6% | 14.3% | 12.3% |
| Unemployment rate B23025 | 7.5% | 6.1% | 4.3% |
| Civilian labor force B23025 | 18,562 | 243,262 | 3,472,016 |
| Mean commute (minutes) B08013 | 32.1 | 28.5 | 24.1 |
| Bachelor's degree or higher B15003 | 26.1% | 25.8% | 29.5% |
| Housing units B25001 | 16,213 | 217,436 | 2,976,568 |
| Owner-occupied B25003 | 70.5% | 71.7% | 70.6% |
| Renters B25003 | 29.5% | 28.3% | 29.4% |
| Median home value B25077 | $211,400 | $230,600 | $218,200 |
| Median gross rent B25064 | $1,282 | $1,131 | $1,062 |
| White, not Hispanic B03002 | 33.4% | 51.4% | 75.4% |
| Black B03002 | 46.1% | 22.7% | 9.1% |
| Hispanic or Latino B03002 | 15.6% | 20.9% | 8.6% |
| Asian B03002 | 1.0% | 1.6% | 2.6% |
| American Indian and Alaska Native B03002 | 0.0% | 0.1% | 0.1% |
Economy now FRED unemployment 3.4% in Sep 2026 (3.7% a year earlier); per capita personal income $66,455 in 2025, up 28% in five years (+3.2% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Merrillville, IN.
Comments